๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sapporo
Clinical trial register · Japan

Clinical Trials in Sapporo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Nagoya 53 Sapporo 41 Kashiwa 39 Yokohama 33 Tลon 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC41 Novartis Pharmaceuticals34 Bristol-Myers Squibb24 AbbVie18 Pfizer18 Clear sponsor filter
Site location
Nagoya53 Sapporo41 Kashiwa39 Yokohama33 Tลon23
All 114 locations
Target enrolment
to

Trials with a site in Sapporo

41 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
NCT07302347Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
DrugPembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
20
Nagoya, Sapporo, Kobe, Chลซล, Fukuoka, Kyoto
2026-06-23
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tลon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
DrugsSacituzumab tirumotecan·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
900
Nagoya, Kurume, ลŒta, Sapporo, Akashi, Shiwa-gun, Hidaka, Sunto-gun,
2026-02-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsSacituzumab tirumotecan·Paclitaxel·Bevacizumab·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,023
Nagoya, Tลon, Kurume, ลŒta, Sapporo, Akashi, Shiwa-gun, Yokohama
2026-01-19
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsLiposomal doxorubicin·Patritumab deruxtecan·Xeloda·Abraxane
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Matsuyama, Sapporo, Tsu, Hirakata, Sakai, Hidaka, Sunto-gun
2025-07-21
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Cetuximab·Adrucil
Merck Sharp & Dohme LLC
Phase 3
477
Nagoya, Kashiwa, Sapporo, Kita-gun, Yokohama, Sendai, Sakai, Hidaka
2025-07-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsXeloda·Epirubicin·Adriamycin·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Nagoya, Matsuyama, Sapporo, Kahoku-gun, Yokohama, Tsu, Naha, Hirakata
2025-06-30
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Nagoya, Sapporo, Ginowan, tabashi City, Fukuoka, Kyoto
2025-06-09
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Nagoya, Matsuyama, Tลon, Kurume, ลŒta, Sapporo, Akashi, Shiwa-gun
2025-05-22
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Nagoya, Sakura, Tลon, Kitakyushu, Kurume, Sapporo, Kobe, Kahoku-gun
2025-05-13
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Nagoya, Toyoake, Sapporo, Sendai, Hirakata, Izumo, Bunkyo, Chลซล
2025-04-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Avastin
Merck Sharp & Dohme LLC
Phase 3
770
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, ลŒta, Sapporo, Shiwa-gun
2025-04-09
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Kashiwa, Matsuyama, Sapporo, Kahoku-gun, Isehara, Kawasaki, Sagamihara
2025-03-16
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, Ohta, Sapporo, Tsukuba
2024-07-24
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Toyoake, Tลon, Sapporo, Kobe, Kanazawa, Tsu, Sendai, Hirakata
2024-07-16
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Nagoya, Kashiwa, ลŒta, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama
2024-06-24
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
600
Nagoya, Toyoake, Kashiwa, Matsuyam, Fukuoka, Kurume, ลŒta, Sapporo
2024-05-24
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu
2024-04-14
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Sakura, Tลon, Kitakyushu, Kurume, Asahikawa, Sapporo, Kobe, Mukai-awagasaki
2023-12-31
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib
Merck Sharp & Dohme LLC
Phase 3
340
Toyoake, Kashiwa, Tลon, Sapporo, Kobe, Kanazawa, Tsu, Sendai
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Sakura, Eiheiji-cho,Yoshida-gun, Kitakyushu, Sapporo, Kobe, Mukai-awagasaki, Kita, Yokohama
2023-12-18
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Maebashi, Sapporo, Kobe, Sendai, Sakai, Izumo, Koto
2023-12-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAdriamycin·Abraxane·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
710
Nagoya, Matsuyama, Tลon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun
2023-12-06
Active, closed
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
NCT06041802Squamous Cell Carcinoma
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
19
Nagoya, Sapporo, Yokohama, Sendai, Matsumoto, Niigata, Hidaka, Izumo
2023-10-20
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
14,550
Nagoya, Toyota, Matsudo, Itoshima, Kasuga, Kitakyushu, Nakagawa, Sapporo
2023-10-09
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
NCT06212752Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
39
Toyoake, Kurume, Otashi, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-06-13
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Toyoake, Kurume, ลŒta, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-02-14
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Nagoya, Sapporo, Isehara, Sendai, Sakai, Chuo-ku, Koto, Fukuoka
2022-07-21
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
DrugsPembrolizumab/Vibostolimab·Paraplatin·Tecentriq·Etoposide
Merck Sharp & Dohme LLC
Phase 3
460
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai
2022-03-24
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Toyoake, Kashiwa, Sakura, Tลon, Sapporo, Yokohama, Kashihara, Sakai
2022-03-15
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Keytruda
Merck Sharp & Dohme LLC
Phase 3
280
Kashiwa, Matsuyama, Tลon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun Yahaba-cho
2022-02-03
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
DrugsZilovertamab vedotin·Granulocyte Colony-Stimulating Factor·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 2/3
290
Sapporo, Isehara, Tsu, Hirakata, Bunkyo, Minato, Chลซล, Fukuoka
2022-01-14
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Paclitaxel·Bevacizumab·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, Sapporo, Shiwa-gun Yahaba-cho, Kawasaki
2021-12-13
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
DrugBelzutifan
Merck Sharp & Dohme LLC
Phase 2
355
Sapporo, Yokohama, Nankoku, Chuo-ku, Kyoto, Tokyo
2021-08-12
Active, closed
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
NCT04956692Non-Small Cell Lung Cancer
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
531
Toyoake, Tลon, Kurume, Sapporo, Kanazawa, Yokohama, Natori-shi, Sendai
2021-08-05
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda
Merck Sharp & Dohme LLC
Phase 3
1,854
Toyoake, Kashiwa, Tลon, Sapporo, Yokohama, Kashihara, Sayama, Suita
2021-04-14
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231Carcinoma, Renal Cell
DrugsBelzutifan·Cabozantinib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
747
Toyoake, Kashiwa, Sakura, Sapporo, Kobe, Yokohama, Kashihara, Sakai
2021-02-25
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
DrugsKeytruda·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
990
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, ลŒta, Sapporo, Akashi
2021-01-10
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
DrugsBelzutifan·Everolimus
Merck Sharp & Dohme LLC
Phase 3
755
Toyoake, Kashiwa, Tลon, Sapporo, Yokohama, Kashihara, Sayama, Suita
2020-02-27
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
DrugsEpirubicin·Doxorubicin·Cyclophosphamide·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,240
Nagoya, Kashiwa, Sapporo, Nishinomiya, Sagamihara, Kumamoto, Hidaka, Kitaadachi-gun
2018-12-27
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
3,500
Nagoya, Kashiwa, Matsuyama, Tลon, Kurume, Sapporo, Akashi, Himeji
2018-08-21
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-japan/city/sapporo

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Sapporo that also match the filters currently applied.

How many clinical trials are recruiting in Sapporo?

21 of the 41 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sapporo), 41 studies
PhaseStudiesRecruitingShare
Phase 3341782.9%
Phase 25212.2%
Phase 1/2112.4%
Phase 2/3112.4%

Most active sponsors

Lead sponsors with the most studies (Sapporo)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC4121
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.